ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...
Fierce Biotech

ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

ImmunityBio: Why I Am Upgrading To A Buy For 2026

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
BioWorld

Immunitybio’s CAR-NK shows complete responses in Waldenström’s

Early data of Waldenström’s non-Hodgkin lymphoma patients enrolled in a trial testing Immunitybio Inc.’s off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK), ...